Medication info
Irostastatin 5 mg (Rosuvastatin Calcium)

Irostastatin 5 mg (Rosuvastatin Calcium)

Prescription medicationTablet
Ingredient · strength
Rosuvastatin Calcium›5.2mg / 1 tablet
Manufacturer / importer
IYON Pharmaceuticals Co., Ltd.
Appearance
Yellow, round, film-coated tablet
Packaging
28 tablets/PTP (14 tablets/PTP × 2), 30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 201908080 · Approved 2019.11.26 · Insurance code 658603950

Summary

Main use
Improvement of dyslipidemia, reduction of cardiovascular disease risk, and inhibition of atherosclerosis progression
Who uses it
Adults · Children
Adult dosage
1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 milligrams daily. 3. Elderly patients: No dose adjustment is necessary. 4. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering this medicine at 20mg to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score above 9. Do not administer this medicine to patients with active liver disease. 6. Race: Since systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients.
Children's dosage
Ages 10 to 17 years: The usual dose range is 5 milligrams to 20 milligrams once daily. (There are no clinical data on doses higher than 20 milligrams in pediatric patients.) The dose should be adjusted individually according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or longer. Under 10 years: Safety and efficacy have not been established.

Ingredients

Manufacturer
IYON Pharmaceuticals Co., Ltd.

Efficacy & effects

Improvement of dyslipidemia, reduction of cardiovascular disease risk, and inhibition of atherosclerosis progression

  • Hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • atherosclerosis
  • polygenic familial hypercholesterolemia
  • primary dysbetalipoproteinemia
  • coronary heart disease
  • elevated high-sensitivity C-reactive protein
  • hypertension
  • low HDL cholesterol
  • smoking
View approved original text

This medication is primarily used as an adjunct when dietary therapy and exercise are not sufficient for patients with primary hypercholesterolemia and mixed dyslipidemia. It is also used as an adjunctive therapy in patients with homozygous familial hypercholesterolemia in conjunction with other lipid-lowering therapies. In patients with hypercholesterolemia, it lowers total cholesterol and LDL cholesterol levels, slowing the progression of atherosclerosis. It may also be used as an adjunct to diet for pediatric patients aged 10 to 17 years who meet specific criteria for heterozygous familial hypercholesterolemia. Additionally, it is effective as an adjunct to dietary therapy in patients with primary dysbetalipoproteinemia. Furthermore, it helps reduce the risk of stroke, myocardial infarction, and vascular revascularization procedures in men over 50 years and women over 60 years with elevated high-sensitivity C-reactive protein levels and additional cardiovascular disease risk factors.

Dosage and Administration

Adult dosage

1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 milligrams daily. 3. Elderly patients: No dose adjustment is necessary. 4. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering this medicine at 20mg to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score above 9. Do not administer this medicine to patients with active liver disease. 6. Race: Since systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients.

Children's dosage

Ages 10 to 17 years: The usual dose range is 5 milligrams to 20 milligrams once daily. (There are no clinical data on doses higher than 20 milligrams in pediatric patients.) The dose should be adjusted individually according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or longer. Under 10 years: Safety and efficacy have not been established.

Precautions

This medication should not be used in certain patients. For example, individuals who are allergic to the ingredients of this medication, those with active liver disease, muscle disorders, those taking cyclosporine, patients with severe renal impairment, and pregnant or nursing women should avoid using this medication. Additionally, individuals at high risk for muscle disorders should avoid high doses. This medication contains lactose, so those with lactose intolerance should also refrain from taking it. Caution is necessary for those with poor liver function or heavy alcohol consumption while taking this medication. It is advisable to monitor liver function by repeating liver enzyme tests before and during treatment. If symptoms of muscle pain or weakness occur, the physician should be notified immediately, and the medication may need to be discontinued if necessary. Particular caution is required for those with impaired kidney function, hypothyroidism, elderly patients, and those with alcohol abuse history who may be more susceptible to muscle disorders. During treatment with this medication, rare side effects such as skin rash, headache, dizziness, gastrointestinal discomfort, and muscle pain may occur. Most are mild and temporary, but if symptoms are severe or persist, medical consultation is required. Additionally, this medication may interact with other drugs, so it is essential to inform the physician or pharmacist if other medications are being taken. Particularly, concomitant use with specific antiviral medications, immunosuppressants, some antibiotics, and fibrate medications may increase the risk of muscle damage. Pregnant or nursing women should not use this medication, and women of childbearing potential should use appropriate contraceptive measures. Caution is necessary because taking this medication during pregnancy could harm the fetus. In the case of overdose, there is no specific antidote, so immediate medical attention should be sought for appropriate treatment, and liver function and muscle enzyme tests should be conducted to assess the condition. Dizziness may occur with this medication, so caution is advised during driving or operation of machinery.

Side effects

Hypersensitivity reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, itching, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, myasthenia gravis, cough, dyspnea, diarrhea, ocular myasthenia, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms syndrome, drug eruption resembling lichen planus, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, liver failure, cognitive impairment, increased ALT, chest pain, muscle cramps, gout, erectile dysfunction, numbness, paresthesia, chest discomfort, anorexia, abdominal distension, syncope, generalized pain, fatigue

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and humidity, so it should be stored in a tightly closed container. It is important to maintain a storage temperature between 1 and 30 degrees Celsius to preserve the medication's effectiveness and safety.

Appearance and packaging

Appearance

Yellow, round, film-coated tablet

Package unit

28 tablets/PTP (14 tablets/PTP × 2), 30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.